Home LiteratureArticle Details
PMID: 21763970 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

mTOR inhibitors in advanced renal cell carcinoma.

Hematology/oncology clinics of North America ·Vol. 25 ·No. 4 ·2011-08-00 ·Pages 835-52

Voss MH, Molina AM, Motzer RJ

Abstract

Better understanding of the molecular biology of renal cell carcinoma (RCC) has led to the development of several targeted anti-cancer agents, several of which have since received approval for treatment of advanced disease. Two of these, the intravenous agent temsirolimus and the oral everolimus, exhibit antitumor effects through inhibition of the mammalian target of rapamycin (mTOR) pathway. This article reviews their mechanisms of action in the context of the current understanding of RCC pathophysiology, the clinical data leading to their approval, class-specific toxicities, potential molecular mechanisms behind treatment resistance and novel treatment approaches for RCC that incorporate mTOR blockade.

MeSH Terms
Carcinoma, Renal Cell/drug therapy,metabolism Clinical Trials as Topic Everolimus Humans Kidney Neoplasms/drug therapy,metabolism Protein Kinase Inhibitors/adverse effects,therapeutic use Sirolimus/adverse effects,analogs & derivatives,therapeutic use TOR Serine-Threonine Kinases/antagonists & inhibitors,metabolism Treatment Outcome
Chemicals
Protein Kinase Inhibitors temsirolimus Everolimus TOR Serine-Threonine Kinases Sirolimus
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Voss Martin H
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 353 East 68th Street, New York, NY 10065, USA.
Molina Ana M
Motzer Robert J
References (95)
95 references, click to expand
  1. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.
    Cancer Res. 2004 Jan 1;64(1):252-61 PMID: 14729632
  2. The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases.
    Cancer. 2011 Jan 15;117(2):290-300 PMID: 20830770
  3. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer.
    J Clin Invest. 2008 Sep;118(9):3065-74 PMID: 18725988
  4. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.
    Cancer. 2010 Sep 15;116(18):4256-65 PMID: 20549832
  5. Activation of the mTOR signaling pathway in renal clear cell carcinoma.
    J Urol. 2007 Jan;177(1):346-52 PMID: 17162089
  6. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
    N Engl J Med. 2007 May 31;356(22):2271-81 PMID: 17538086
  7. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.
    Curr Biol. 2004 Jul 27;14(14):1296-302 PMID: 15268862
  8. Everolimus- and temsirolimus-associated enteritis: report of three cases.
    J Clin Oncol. 2011 May 10;29(14):e404-6 PMID: 21357780
  9. regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis.
    Diabetes. 2004 Nov;53(11):2748-56 PMID: 15504954
  10. A complex interplay between Akt, TSC2 and the two mTOR complexes.
    Biochem Soc Trans. 2009 Feb;37(Pt 1):217-22 PMID: 19143635
  11. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
    Cancer. 2004 Feb 15;100(4):657-66 PMID: 14770419
  12. Lack of KRAS and BRAF mutation in renal cell carcinoma.
    Eur Urol. 2009 Jun;55(6):1490-1 PMID: 19282104
  13. The biology and clinical relevance of the PTEN tumor suppressor pathway.
    J Clin Oncol. 2004 Jul 15;22(14):2954-63 PMID: 15254063
  14. Targeting the mTOR signaling network for cancer therapy.
    J Clin Oncol. 2009 May 1;27(13):2278-87 PMID: 19332717
  15. mTOR inhibitors: an overview.
    Liver Transpl. 2001 Jun;7(6):473-84 PMID: 11443573
  16. Regulation of cell survival and proliferation by the FOXO (Forkhead box, class O) subfamily of Forkhead transcription factors.
    Biochem Soc Trans. 2003 Feb;31(Pt 1):292-7 PMID: 12546704
  17. Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients.
    Clin J Am Soc Nephrol. 2010 Apr;5(4):703-8 PMID: 20093343
  18. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1.
    Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4640-5 PMID: 11287630
  19. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Circulation. 2004 Jul 13;110(2):227-39 PMID: 15249516
  20. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.
    J Clin Oncol. 2010 Feb 20;28(6):1061-8 PMID: 20100962
  21. Rapamycin is an effective inhibitor of human renal cancer metastasis.
    Kidney Int. 2003 Mar;63(3):917-26 PMID: 12631072
  22. Modulation of insulin receptor substrate-1 tyrosine phosphorylation by an Akt/phosphatidylinositol 3-kinase pathway.
    J Biol Chem. 1999 Apr 2;274(14):9351-6 PMID: 10092613
  23. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis.
    J Cell Biol. 2004 Nov 8;167(3):399-403 PMID: 15533996
  24. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth.
    PLoS Biol. 2003 Dec;1(3):E83 PMID: 14691554
  25. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
    Lancet. 2007 Dec 22;370(9605):2103-11 PMID: 18156031
  26. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.
    Diabetes Care. 2009 Jan;32(1):193-203 PMID: 18945920
  27. Targeting mTOR in renal cell carcinoma.
    Cancer. 2009 May 15;115(10 Suppl):2313-20 PMID: 19402072
  28. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.
    J Antibiot (Tokyo). 1975 Oct;28(10):727-32 PMID: 1102509
  29. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Expert Opin Investig Drugs. 2010 Aug;19(8):919-30 PMID: 20569080
  30. Rapamycin: a novel immunosuppressive macrolide.
    Med Res Rev. 1994 Jan;14(1):1-22 PMID: 8309312
  31. Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma.
    Anticancer Drugs. 2010 Jun;21(5):478-86 PMID: 20401967
  32. The PI3K pathway as drug target in human cancer.
    J Clin Oncol. 2010 Feb 20;28(6):1075-83 PMID: 20085938
  33. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.
    Cancer. 2007 Jun 1;109(11):2257-67 PMID: 17440983
  34. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
    Cancer Res. 2005 Aug 15;65(16):7052-8 PMID: 16103051
  35. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
    Ann Clin Lab Sci. 2006 Summer;36(3):283-93 PMID: 16951269
  36. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.
    Blood. 2008 Jan 1;111(1):379-82 PMID: 17878402
  37. Upstream and downstream of mTOR.
    Genes Dev. 2004 Aug 15;18(16):1926-45 PMID: 15314020
  38. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.
    J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 PMID: 8433390
  39. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.
    Oncogene. 2007 Mar 22;26(13):1932-40 PMID: 17001314
  40. Temsirolimus in VEGF-refractory metastatic renal cell carcinoma.
    Ann Oncol. 2011 Jan;22(1):145-148 PMID: 20595449
  41. Mutations in the ras protooncogenes are rare events in renal cell cancer.
    Eur J Cancer. 1992;28(2-3):333-6 PMID: 1591047
  42. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.
    J Clin Invest. 2010 Aug;120(8):2858-66 PMID: 20664172
  43. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.
    Clin Cancer Res. 2001 Jun;7(6):1758-64 PMID: 11410517
  44. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma.
    Clin Genitourin Cancer. 2009 Jan;7(1):24-7 PMID: 19213664
  45. Everolimus in clinical practice--renal transplantation.
    Nephrol Dial Transplant. 2006 Jul;21 Suppl 3:iii18-23 PMID: 16815852
  46. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology.
    J Clin Oncol. 2002 May 1;20(9):2376-81 PMID: 11981011
  47. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.
    Cancer. 2009 Jun 1;115(11):2438-46 PMID: 19306412
  48. Defining the role of mTOR in cancer.
    Cancer Cell. 2007 Jul;12(1):9-22 PMID: 17613433
  49. Hypoxia-inducible factors: central regulators of the tumor phenotype.
    Curr Opin Genet Dev. 2007 Feb;17(1):71-7 PMID: 17208433
  50. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.
    Endocr Relat Cancer. 2001 Sep;8(3):249-58 PMID: 11566616
  51. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation.
    Mol Cell Biol. 2002 Aug;22(15):5575-84 PMID: 12101249
  52. Development and validation of a scale to measure disease-related symptoms of kidney cancer.
    Value Health. 2007 Jul-Aug;10(4):285-93 PMID: 17645683
  53. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.
    J Clin Oncol. 2004 Jun 15;22(12):2336-47 PMID: 15136596
  54. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma.
    Am J Respir Crit Care Med. 2010 Aug 1;182(3):396-403 PMID: 20194812
  55. The Akt-mTOR tango and its relevance to cancer.
    Cancer Cell. 2005 Sep;8(3):179-83 PMID: 16169463
  56. High-throughput oncogene mutation profiling in human cancer.
    Nat Genet. 2007 Mar;39(3):347-51 PMID: 17293865
  57. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.
    Clin Cancer Res. 2006 Oct 1;12(19):5755-63 PMID: 17020981
  58. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features.
    Ann Oncol. 2008 Aug;19(8):1387-1392 PMID: 18385198
  59. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
    N Engl J Med. 2007 Jan 11;356(2):115-24 PMID: 17215529
  60. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.
    N Engl J Med. 2003 Aug 28;349(9):847-58 PMID: 12944570
  61. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle.
    J Antibiot (Tokyo). 1975 Oct;28(10):721-6 PMID: 1102508
  62. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
    N Engl J Med. 2003 Jul 31;349(5):427-34 PMID: 12890841
  63. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.
    J Clin Oncol. 2010 May 1;28(13):2131-6 PMID: 20368560
  64. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.
    J Clin Oncol. 2004 Feb 1;22(3):454-63 PMID: 14752067
  65. Targeting mTOR in cancer: renal cell is just a beginning.
    Target Oncol. 2010 Dec;5(4):269-80 PMID: 20563661
  66. Hypoxia-inducible factor-2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor.
    BJU Int. 2008 Aug;102(3):358-63 PMID: 18394010
  67. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2.
    J Biol Chem. 2008 Dec 12;283(50):34495-9 PMID: 18945681
  68. Profiling critical cancer gene mutations in clinical tumor samples.
    PLoS One. 2009 Nov 18;4(11):e7887 PMID: 19924296
  69. The TOR pathway: a target for cancer therapy.
    Nat Rev Cancer. 2004 May;4(5):335-48 PMID: 15122205
  70. Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer.
    Invest New Drugs. 2010 Jun;28(3):334-42 PMID: 19415181
  71. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.
    Cancer Res. 2006 Feb 1;66(3):1500-8 PMID: 16452206
  72. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
    Semin Oncol. 2009 Dec;36 Suppl 3:S3-S17 PMID: 19963098
  73. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
    J Clin Oncol. 2008 Nov 20;26(33):5422-8 PMID: 18936475
  74. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition.
    Mol Cancer Ther. 2009 Apr;8(4):742-53 PMID: 19372546
  75. AKT/PKB signaling: navigating downstream.
    Cell. 2007 Jun 29;129(7):1261-74 PMID: 17604717
  76. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer.
    Annu Rev Cell Dev Biol. 2001;17:615-75 PMID: 11687500
  77. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
    Mol Cancer Ther. 2005 Oct;4(10):1533-40 PMID: 16227402
  78. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2.
    Blood. 2009 Oct 1;114(14):2926-35 PMID: 19641186
  79. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies.
    Med Oncol. 2009;26(2):202-9 PMID: 19229667
  80. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
    Lancet. 2008 Aug 9;372(9637):449-56 PMID: 18653228
  81. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
    Cancer Res. 2002 Sep 1;62(17):5027-34 PMID: 12208757
  82. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.
    Nat Med. 2006 Jan;12(1):122-7 PMID: 16341243
  83. Standards of medical care in diabetes--2010.
    Diabetes Care. 2010 Jan;33 Suppl 1:S11-61 PMID: 20042772
  84. Sorafenib in advanced clear-cell renal-cell carcinoma.
    N Engl J Med. 2007 Jan 11;356(2):125-34 PMID: 17215530
  85. Activity of rapamycin (AY-22,989) against transplanted tumors.
    J Antibiot (Tokyo). 1984 Oct;37(10):1231-7 PMID: 6501094
  86. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.
    Clin Genitourin Cancer. 2007 Sep;5(6):379-85 PMID: 17956710
  87. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.
    J Clin Oncol. 2008 Apr 1;26(10):1596-602 PMID: 18332467
  88. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.
    J Clin Oncol. 2002 Jan 1;20(1):289-96 PMID: 11773181
  89. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.
    Science. 2005 Feb 18;307(5712):1098-101 PMID: 15718470
  90. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.
    Cancer Res. 2001 Feb 15;61(4):1527-32 PMID: 11245461
  91. Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha.
    Cancer. 2009 Aug 15;115(16):3651-60 PMID: 19526589
  92. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
    J Clin Oncol. 2004 Mar 1;22(5):909-18 PMID: 14990647
  93. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.
    J Clin Oncol. 2008 Apr 1;26(10):1588-95 PMID: 18332470
  94. TOR signaling in growth and metabolism.
    Cell. 2006 Feb 10;124(3):471-84 PMID: 16469695
  95. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy.
    Clin Cancer Res. 2007 Jun 1;13(11):3109-14 PMID: 17545512
Article Info
Journal
Hematology/oncology clinics of North America
Abbr.
Hematol Oncol Clin North Am
ISSN
1558-1977
DOI
10.1016/j.hoc.2011.04.008
Published
2011-08-00
Pages
835-52
Language
English
Region
United States
NLM ID
8709473
PMCID
PMC3587783
Subset
IM
Grants
NCI NIH HHS · R25 CA020449 · United States
NCI NIH HHS · T32 CA009207 · United States
External Links
PubMed source DOI: 10.1016/j.hoc.2011.04.008 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2